|CATEGORY||Salut, Covid-19, Vacunes|
|DATE:||April 05 2021|
The second vaccine developed in Russia is EpiVacCorona. There is still little information about this vaccine, which has already been approved by the government, but as of 19 March was not yet being used to immunise the population.
Manufactured by the State Research Center of Virology and Biotechnology VECTOR, EpiVacCorona is a vaccine based on synthetic peptides. Its composition includes a synthetic version of SARS-CoV-2 protein fragments (or peptides) to trigger the immune response in the body. The phase III clinical trial began in November 2020 and involved about 3,000 volunteers from Russia. The results have not yet been published, but officials assured that it offered 100% efficacy during phases I and II. It consists of two doses, administered over 21 to 28 days.
It is not known at this stage whether it causes adverse reactions and there is no information on the temperature at which it should be stored.